Faculty Collaboration Database

Gender disparities in the National Institutes of Health funding for hematologic malignancies and cellular therapies. Leuk Lymphoma 2022 Jul;63(7):1708-1713

Date

02/11/2022

Pubmed ID

35142581

DOI

10.1080/10428194.2022.2038378

Scopus ID

2-s2.0-85125151936 (requires institutional sign-in at Scopus site)   4 Citations

Abstract

We investigated gender inequality in the National Institutes of Health (NIH) funding for hematologic malignancies and cellular therapies (HMCT). The data were retrieved from the NIH Research Portfolio Online Reporting Tools (RePORT). In 2018-2019, 1834 grants totaling $799 million were awarded (men 71% vs. women 29%) to 975 principal investigators (PIs), including 680 (70%) male PIs and 295 (30%) female PIs. There was no significant gender difference in the mean grant amount per PI. Male PIs as compared to female PIs had a higher h-index (44 vs 31, p < 0.001), a higher number of publications (159.5 vs 94, p < 0.001), and higher years of active research (26 vs 21, p < 0.001). In multivariate analyses, a higher h-index independently predicted a higher mean grant amount per PI (p = 0.010), and female PIs were independently less likely to have a higher h-index (p < 0.001). Our study shows significant gender disparity in the NIH funding for HMCT research.

Author List

Siddiqui RS, Chaudhary SG, Shahzad M, Anwar I, Hussain A, Ahmed N, Abhyankar SH, Shune L, Hematti P, Male H, Khosa F, Lin T, McGuirk JP, Callander NS, Mushtaq MU

Author

Peiman Hematti MD Professor in the Medicine department at Medical College of Wisconsin

MESH terms used to index this publication - Major topics in bold

Biomedical Research
Female
Hematologic Neoplasms
Humans
Male
National Institutes of Health (U.S.)
Sex Factors
United States